This week, we read a proposal for a global diamond open access research infrastructure, we take a look at the most-read Scholarly Kitchen posts of 2023 and we consider the role of alternative open access publishing models in the publication of rebuttals to existing papers. Finally, we read the Open Pharma blog Editor’s pick and listen to reflections on the founding of Open Pharma.
Proposing a global diamond open access infrastructure via Hypotheses | 20-minute read
The diamond open access model facilitates the publishing of research outputs without charging either authors or readers. Here, Pierre Mounier (Co-coordinator at OPERAS and Associate Director for International Development at OpenEdition) and Johan Rooryck (Executive Director at cOAlition S) propose a diamond open access research infrastructure that aims to support communities worldwide.
2023 highlights from The Scholarly Kitchen via The Scholarly Kitchen | 4-minute read
In the first post of the year from The Scholarly Kitchen, David Crotty (Senior Consultant at Clarke & Esposito) reflects on key developments from the world of academic publishing in 2023. He also signposts the most-read Scholarly Kitchen articles of 2023 and predicts areas of priority for the publishing and communications community in 2024.
Should authors be charged APCs for rebuttals? via Walled Culture | 3-minute read
Article processing charges (APCs) are often used by publishers to fund the publishing of open access articles. However, this publication model may be disincentivizing authors from publishing critiques of existing publications. In this post, Glyn Moody (freelance journalist, author and speaker) argues that alternative publication models – such as diamond open access – should be considered to allow for the timely publication of rebuttals without cost to either the author or reader.
Open Pharma Editor’s pick via Open Pharma | 6-minute read
Since the founding of Open Pharma in 2017, the Open Pharma blog has provided a platform for contributors to share developments from the world of open science. This Editor’s pick of articles from the Open Pharma blog archive has been curated to review the changing conversations in open science over the past 6 years.
Reflecting on the founding of Open Pharma via Open Pharma | 7-minute watch
In late 2023, Open Pharma co-founders Chris Winchester (CEO of Oxford PharmaGenesis) and Chris Rains (Head of CPR BioPharma Consulting) sat down to take a retrospective look at the founding of Open Pharma and to discuss their visions for the future of pharma communications. Watch the full discussion now on the Open Pharma YouTube channel.